tiprankstipranks
Trending News
More News >

EQL Pharma Expands into Germany and the Netherlands

Story Highlights
EQL Pharma Expands into Germany and the Netherlands

Don’t Miss TipRanks’ Half-Year Sale

EQL Pharma AB ( (SE:EQL) ) has provided an update.

EQL Pharma AB is expanding its operations into Germany and the Netherlands by recruiting local market experts to identify and launch niche generics. The company plans to replicate its successful Nordic strategy in these new markets, with potential for significant financial impact within 3-4 years. EQL also aims to expand further into Austria, Switzerland, Belgium, and Luxembourg. Existing partnerships for specific products will remain strategically important, with potential for new partnerships if deemed beneficial.

More about EQL Pharma AB

EQL Pharma AB specializes in developing and selling generic drugs that are medically equivalent to original drugs, focusing on niche generics with limited competition. The company operates primarily in the Nordic and European markets, concentrating on prescription drugs, including hospital products. EQL Pharma is based in Lund, Sweden, and is listed on the Nasdaq Stockholm stock market. It collaborates with leading contract manufacturers and pharmaceutical companies in the EU and Asia.

Average Trading Volume: 15,975

Current Market Cap: SEK2.65B

For an in-depth examination of EQL stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1